Author:
Ko A H,Hwang J,Venook A P,Abbruzzese J L,Bergsland E K,Tempero M A
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, Rake B, Space S, Westrick B, Schoemaker H, Zurawski Jr VR (1983) Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 29: 549–552
2. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W (1990) Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 50: 6823–6826
3. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V (2000) Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82: 1013–1016
4. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T (2001) Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 91: 490–495
5. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10–30
Cited by
138 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献